



Press release

Dr. Klaus Schwamborn Joins Advisory Board of EBViously GmbH

May 6th 2025

EBViously GmbH is pleased to announce that Dr. Klaus Schwamborn, Head of Vaccine Development at the German Center for Infection Research (DZIF), has joined the company's advisory board as DZIF representative.

Dr. Schwamborn brings extensive R&D and leadership experience from different international industrial organizations. He has a long-standing track record in translating product candidates from research into early clinical studies. Over 10 years he has been with Valneva and was involved in progressing different vaccine candidates. In his current role at DZIF he is responsible for managing the vaccine and antibody portfolio and supporting scientists to advance innovative projects and assets into the clinic. His expertise will be invaluable as EBViously continues to develop a cutting-edge vaccine for prevention of Epstein-Barr virus (EBV)-related diseases. EBV-001 is the lead candidate that will enter into clinical trials early next year.

"We are honored to welcome Dr. Schwamborn to our advisory board," said Sebastian Goy, CEO of EBViously GmbH. "His scientific and business insight and background, together with his strategic vision, will greatly support our important mission to address the unmet medical need related to EBV-associated diseases."

Dr. Schwamborn stated, "I am highly excited to join EBViously's advisory board at this critical stage of development. With a unique approach and world class scientific team, EBViously is developing a vaccine candidate that has the potential to become a best-in class vaccine, able to tackle various EBV-driven conditions."

This appointment underscores EBViously's commitment to strengthen scientific excellence and strategic collaboration as it advances its R&D pipeline.

About EBViously

EBViously specializes in novel vaccines based on next-generation virus-like particles. The Company is a spin-off from Helmholtz Munich (HMGU) and is led by a group of renowned experts in the field of Epstein-Barr virus research. EBViously has so far received more than €10 million in funding from the German Center for Infection Research (DZIF) and Helmholtz Validierungs Fonds (HVF). The clinical trial is planned with EBViously's collaboration partners at Ludwig-Maximilians-Universität München (LMU).

About EBV

Epstein-Barr virus is one of the nine known herpesviruses and one of the most common viruses found in humans. It is estimated that approximately 90% of the world's population is infected with EBV. Infections typically occur in early childhood and are usually asymptomatic. However, when infections occur later in life, they frequently cause infectious mononucleosis ("glandular fever"), chronic fatigue syndrome and other serious complications. The virus is also associated with certain cancers - approximately 200,000 cancer cases worldwide, including several types of lymphoma, are attributed to EBV. In 2022, a large study documented that EBV infection is by far the most important risk factor for multiple sclerosis. A history of infectious mononucleosis further increases the risk.

Company Contact

For media inquiries, please contact:

EBViously
Sebastian Goy (CEO)
info@ebviously.com

Chief Executive Office